HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Pr... (p and physical and mental well-being. ...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity

Date:6/12/2008

p> and physical and mental well-being. Again, those with better HAQ

scores had improved performance while at work.

About Rheumatoid Arthritis

Unlike osteoarthritis, the most common form of arthritis, RA is a chronic, autoimmune disease characterized by joint inflammation, joint pain and stiffness, which can lead to long-term joint damage. The joints most commonly affected early in the disease are the smaller joints of the fingers, feet and wrists. The elbows, knees, ankles and hips can also be affected. Although there is no cure for RA, people continue to seek treatments that help alleviate pain and inflammation and slow disease progression.

More information on RA and current treatment options can be found at http://www.RA.com.

Important Safety Information

Globally, prescribing information varies; refer to the individual country product label for complete information.

Serious infections, sepsis, rare cases of tuberculosis (TB), and opportunistic infections, including fatalities, have been reported with the use of TNF antagonists, including HUMIRA. Many of the serious infections have occurred in patients on concomitant immunosuppressive therapy that, in addition to their underlying disease could predispose them to infections. Patients must be monitored closely for infections, including tuberculosis, before, during and after treatment with HUMIRA. Treatment should not be initiated in patients with active infections until infections are controlled. HUMIRA should not be used by patients with active TB or other severe infections such as sepsis and opportunistic infections. Patients who develop new infections while using HUMIRA should be monitored closely. HUMIRA should be discontinued if a patient develops a new serious infection until infections are controlled. Physicians should exercise caution when considering use of HUMIRA in patients with a history of recurring infect
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
2. Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
3. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
4. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
5. Data Show that Abbotts HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
6. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
7. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
8. Treating diabetes during pregnancy can break link to childhood obesity
9. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
10. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
11. Family-based treatment more effective than supportive psychotherapy in treating bulimia

Post Your Comments:

(Date:5/18/2013)... few extra cups of coffee each month might help ... as primary sclerosing cholangitis (PSC), a new study suggests. ... found that drinking coffee was associated with a reduced ... cirrhosis of the liver, liver failure and biliary cancer. ... "While rare, PSC has extremely detrimental effects," ...

(Date:5/18/2013)... 18, 2013) There are significant cost and ... to diagnose or treat gastrointestinal problems, according to ... , A study by New York Presbyterian Hospital ... testing may substantially reduce the cost and risk ... is believed to affect nearly 25 percent of ...

(Date:5/18/2013)... 2013 Assisted living and retirement ... safety and comfort of their residents. Systems Technologies ... with an effective and cost-efficient solution – VisionLink ... integrated, turnkey communications solution that helps nurses provide ... independence and privacy. , The VisionLink ...

(Date:5/18/2013)... 2013 Transvaginal mesh lawsuits ... move forward in a consolidated litigation underway in New ... According to a notice on the Court’s website, the ... litigation will be held on Wednesday, May 22nd. ... in the proceeding on behalf of women who suffered ...

(Date:5/18/2013)... The “World Healthcare IT Market: Trends & Forecast (2010 ... restraints, and opportunities in North America, Europe, Asia, & ... 89 market data tables , ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers ... healthcare IT market is expected to grow from $99.6 ...

Breaking Medicine News(10 mins):Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2 Health News:New research identifies practice changes to improve value and quality of GI procedures 2 Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2 Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3 Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2 Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3 Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2 Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3

[0] Study Links Coffee to Lower Risk for Rare Liver Disease [0] New research identifies practice changes to improve value and quality of GI procedures [0] VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities [0] Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation [0] Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets

... the form of percutaneous coronary intervention (PCI) is now ... infarction. New European guidelines issued in November 2008 emphasised ... to restore blood flow to the heart and improve ... in patients with stable coronary artery disease; PCI has ...

... Construction Company, the nation,s leading builder of healthcare facilities, ... proceed with the $42 million Phase Two expansion to ... start in March 2009 with completion scheduled for March ... plant, emergency rooms, ICU, CCU, three operating rooms and ...

... PARK, Ill., Feb. 6 Abbott ( NYSE: ABT ... Antitrust,Improvements Act of 1976 (HSR) applicable to Abbott,s cash ... common stock of Advanced Medical,Optics (AMO) expired last night ... The expiration of the HSR waiting period satisfies ...

... of 7 HIV+ Patients Receiving Dapsone Therapy at Significant ... IRVINE, Calif., Feb. 6 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, today announced that a ... Medicine 38th Critical Care Congress suggests providers should consider ...

... revenues increase by 35% over same period in ... are in Canadian dollars unless otherwise noted),BELLEVILLE, ON, ... (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, ... of its 2009 fiscal year, ending December 31, ...

... a new study shows that losing weight is perhaps the ... disorders, according to a new study in the American ... the American Thoracic Society,s three peer-reviewed journals. , Weight ... fancy high-tech treatment, but it is an exciting therapy for ...

Efficacy of stents is improved when their placement is determined by arterial blood flow measurement Turner to Manage Construction of $42 Million Expansion of Northern Inyo Hospital in Bishop, Calif.Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia Bioniche Reports Fiscal 2009 Second Quarter Losing weight can cure obstructive sleep apnea in overweight patients

(Date:5/17/2013)... BEIJING , May 17, 2013 Sinovac Biotech ... vaccines in China , today announced that ... quarter ended March 31, 2013, before market on Tuesday, May ... Tuesday, May 28, 2013, at 8:00 a.m. EDT (May 28, ... Company,s financial results and provide an update on recent corporate ...

(Date:5/16/2013)... ZURICH , May 17, 2013 ... and Research (A*STAR) and Switzerland,s Cytos ... been dosed in a Phase 1 clinical trial with their ... virus-like particle (VLP) technology. In this first Phase 1 clinical ... and its potential to protect against H1N1 influenza infection will ...

(Date:5/16/2013)... 16, 2013 PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...

Breaking Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2 Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6 PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2

[0] Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results [0] A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing [0] PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering

... 14, 2011 Naviscan, Inc., the worldwide leader in ... Cheng MD, PhD has joined the Naviscan Board of ... business experience related to reimbursement in the medical device ... Affairs and Reimbursement at Acclarent, Inc. After acquisition by ...

... Codexis, Inc. (Nasdaq: CDXS ) today announced the ... Technology Leadership Forum, to be held in Vail, CO on ... Financial Officer, will appear on a panel titled "Crude Alternatives: ... 8 at 12:30 p.m. ET. A webcast is not being ...

Cached Medicine Technology:Naviscan Further Strengthens its Board of Directors With the Addition of Dr. Andre Cheng 2

Naviscan Further Strengthens its Board of Directors With the Addition of Dr. Andre Cheng Codexis to Present at the Pacific Crest and Canaccord Genuity Conferences

... Plate Capability The Equalizer 384 includes ... and equal tip spacing, choice of two software ... addition, this model allows you to evenly space ... accessing many gels and for use with 384 ...

... Expandable Tip System A lower cost alternative ... to perform multi-sample transfers between two different vessel ... knob, tip spacing can be quickly and easily ... 96 well plates. Ergonomic Design for Unparalleled ...

... A lower cost alternative to Equalizers, the patented ... between two different vessel configurations. With the push ... be quickly and easily adjusted for test tubes ... Ergonomic Design for Unparalleled Comfort Pick one ...

Medicine Products:

Impact Equalizer 384 8-Channel Electronic Pipettor, 1-30l Impact2 EXP 8-Channel Electronic Pipettor, 15-1250L Impact EXP 8-Channel Electronic Pipettor, 0.5-12.5L Impact2 EXP 6-Channel Electronic Pipettor, 15-1250L